clinical trial · NCT05322096
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Prader-Willi SyndromeRGH-706Placebo
brief summary
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study in the clinical development program for RGH-706. The aim of this study is to evaluate the efficacy, safety, and tolerability of RGH-706 in patients with Prader-Willi Syndrome (PWS).
started
Sep 22, 2022
primary completion
Apr 10, 2024
completion
Apr 10, 2024
last updated
Jun 3, 2024
official title
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol